New drug combo aims to fight recurrent cervical cancer
NCT ID NCT05990803
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two experimental drugs, BL-B01D1 and SI-B003, alone or together, in 130 women with recurrent or metastatic cervical cancer that hasn't responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants receive the drugs through an IV, and the study will also find the best dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-B01D1 (izalontamab brengitecan) and SI-B003, given by intravenous infusion
- What this could lead to
- If successful, this could offer a new treatment option for people with cervical cancer that has returned or spread, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early phase II trial with only 130 participants, so results may not apply to everyone. The drugs may cause side effects or not work as hoped, and the optimal dose is still being explored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment